上海2026年2月13日 /美通社/ -- 发表在《柳叶刀-呼吸病学杂志》的III期KALOS与LOGOS试验阳性完整结果显示:在未控制的哮喘患者中,阿斯利康的倍择瑞®令畅®(布地奈德/格隆溴铵/富马酸福莫特罗,通用名:布地格福吸入气雾剂(320/28.8/9.6μg))与吸入性糖皮质激素/长效β2-受体激动剂(ICS/LABA)双联吸入药物信必可®(布地奈德/富马酸福莫特罗,一种标准治疗方案)、...
Source Link上海2026年2月13日 /美通社/ -- 发表在《柳叶刀-呼吸病学杂志》的III期KALOS与LOGOS试验阳性完整结果显示:在未控制的哮喘患者中,阿斯利康的倍择瑞®令畅®(布地奈德/格隆溴铵/富马酸福莫特罗,通用名:布地格福吸入气雾剂(320/28.8/9.6μg))与吸入性糖皮质激素/长效β2-受体激动剂(ICS/LABA)双联吸入药物信必可®(布地奈德/富马酸福莫特罗,一种标准治疗方案)、...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.